Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Novel chemotherapy‐free combination regimen for ibrutinib‐resistant mantle cell lymphoma

“…The favourable response in our report to a lenalidomide-bortezomib-based combination is in concordance with preclinical data suggesting that lenalidomide can overcome bortezomib resistance (Moros et al, 2014). In the recent Cancer and Leukemia Group B (CALGB) phase 2 trial for the treatment of relapsed/refracory MCL (Morrison et al, 2015), the combination of bortezomib plus lenalidomide achieved a disappointing low ORR (40% with only 15% CRs) which is inferior to what has been reported with either agent when combined with rituximab and/or dexamethasone (Dreyling et al, 2014). Therefore, we speculate that the addition of rituximab and dexamethasone to lenalidomide plus bortezomb in our regimen may have impacted the excellent outcomes.…”

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

“…Despite recent advances, and with the exception of a small patient population eligible for allogeneic stem cell transplantation, there is no globally recognised standard of care in relapsed mantle-cell lymphoma. [3][4][5] Ibrutinib is a fi rst-in-class, once-daily, oral, covalently binding inhibitor of Bruton's tyrosine kinase. Bruton's tyrosine kinase belongs to the cytoplasmic tyrosine kinase family (Tec kinases) and is important for B-cell receptor signalling and other pathways downstream of the B-cell receptor.…”

Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review

“…3,4 For mantle cell lymphoma, auto-HSCT has demonstrated benefits associated with response and survival. 5 For follicular lymphoma, auto-HSCT is not recommended as a consolidation first-line treatment because of its excessive toxicity and lack of benefit for overall survival (OS). 6 However, this therapeutic approach is used in patients with sensitive relapse.…”